Switching PD-1 to BRAF + MEK inhibition improves recurrence-free survival in patients receiving a second course of adjuvant melanoma therapy

Further Publications Immunology

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Acta Derm Venereol

Juan-Carpena G, Martínez Banaclocha N, Palazón Cabanes JC, Niveiro-de Jaime M, Betlloch Mas I, Blanes-Martínez M

doi: 10.2340/actadv.v105.42023

Melanoma and Skin Cancer

Local Recurrence and Survival in Patients With Melanoma In Situ

JAMA Dermatol

Dessinioti C, Befon A, Plaka M, Niforou A, Kypreou K, Geller AC, Stratigos AJ

doi: 10.1001/jamadermatol.2025.3078

Melanoma and Skin Cancer

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21

Br J Dermatol

Mistry K, Jeffrey P, Levell NJ, Kennedy O, Richardson K, Craig P, Bright C, Taylor S, Ragan J, Karponis D, Pethick J, Lavelle K, McRonald F, Hardy S, Vernon S, Lorigan P, Venables ZC

doi: 10.1093/bjd/ljaf351

Melanoma and Skin Cancer

Survival impact of second primary cutaneous and non-cutaneous melanoma in melanoma survivors

J Eur Acad Dermatol Venereol

Xie J, Kiuru M, Pollock BH, Keegan THM

doi: 10.1111/jdv.70043

Psoriatic Arthritis

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

J Rheumatol

Gladman DD, Mease PJ, Gossec L, Husni ME, Gottlieb AB, Ink B, Bajracharya R, Coarse J, Lyris N, Lambert J, Tillett W

doi: 10.3899/jrheum.2024-0923

Melanoma and Skin Cancer

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Melanoma Res

Al-Naesan I, Krepper D, Sparano F, Sztankay M, Efficace F, Giesinger JM

doi: 10.1097/CMR.0000000000001014

Melanoma and Skin CancerFurther Publications Rheumatology

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

J Autoimmun

Tenstad HB, Ruhlmann CH, Möller S, Kjaer S, Bastholt L, Just SA, Lindegaard H

doi: 10.1016/j.jaut.2025.103400

Melanoma and Skin Cancer

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

Melanoma Res

González-Barrallo I, Castellón Rubio VE, Medina J, España Fernández S, Mujika K, Majem M, Aguado C, Cabrera Suárez MÁ, Palacio I, Osterloh L, Martínez-Fernández A, García-Castaño A

doi: 10.1097/CMR.0000000000001020

Rheumatoid Arthritis

Digital behavioral therapy improves outcome in patients with axial spondyloarthritis and persistent pain: a randomized controlled trial

Arthritis Care Res (Hoboken)

Kiefer D, Sonkaya Y, Krause D, Voglau M, Mintrop B, Redeker I, Baraliakos X, Kiltz U

doi: 10.1002/acr.25679

Related content

Association of Cutaneous Immune-related Adverse Events with Overall Survival and Progression-free Survival in Oncology Patients Receiving Immune Checkpoint Inhibitors: A Prospective Study of 189 Patients in a Spanish Tertiary Care Hospital

Local Recurrence and Survival in Patients With Melanoma In Situ

A national cohort study of melanoma BRAF status, testing patterns, patient and tumour characteristics, treatment and survival in England 2016-21

Survival impact of second primary cutaneous and non-cutaneous melanoma in melanoma survivors

Bimekizumab Improves Patient-Reported Outcomes and Work Productivity in Patients with Psoriatic Arthritis: 1-Year Results from Two Phase 3 Studies

Patient-reported outcomes in randomized controlled trials evaluating BRAF inhibitors in patients with cutaneous melanoma: a systematic scoping review of quality of reporting and trial results

Poorer survival for patients with inflammatory arthritis treated with immune checkpoint inhibitors for melanoma

Relation between dabrafenib plus trametinib-induced pyrexia and age in BRAF V600-mutated metastatic melanoma patients: A post hoc analysis of the real-world ELDERLYMEL study

Digital behavioral therapy improves outcome in patients with axial spondyloarthritis and persistent pain: a randomized controlled trial